晨间信号Morning Signal
《新科学家》 2026年10月3日 · 中文解读

肥胖儿童该用GLP-1减肥药吗?

Should children with obesity be treated with GLP-1 drugs? · Alice Klein
约 6 分钟Analysis Health已做好,小程序里马上能听
这篇讲什么
美国8至11岁肥胖儿童的GLP-1处方比例已从2019年的0.03%升至9.3%。监管仅批准12岁以上使用,临床却已触及8岁。长期生长、青春期与营养缺乏的数据仍然缺失。
中文解读 · 试听前 3:00 / 全长 6:38
0:003:00
大壹讲,咪仔问。点字幕可跳到那一句。
试听到此为止。完整解读、逐句字幕和后台播放,在微信小程序「晨间信号」里听。
原文开头
A SMALL but growing proportion of children under the age of 12 with obesity are being prescribed GLP-1 drugs to help them lose weight. There are signs that this successfully treats obesity, but there are also concerns about the drugs’ long-term effects. So, is this trend likely to continue, and should it? Last month, a study led by Babak Orandi at New York University found that 9.3 per cent of children in the US aged 8 to 11 with obesity but without diabetes are being prescribed GLP-1 drugs like semaglutide (Wegovy) and tirzepatide (Zepbound) – up from 0.03 per cent in 2019. …
摘自《新科学家》(New Scientist)2026年10月3日,Alice Klein。仅引用开头一小段供了解文章,版权归原刊所有,全文请阅读原刊。
晨间信号小程序码
微信扫码,在小程序里听完整版
不用登录先听一篇 · 或在微信搜索小程序 晨间信号
同期其他文章